EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM I.V. FORMULATION OF INFLIXIMAB

Phase-IV, national, multicentric, non-randomized, observational real-life study. The goal of this stud is to investigate the patient's benefits in terms of quality of life and work ability resulting from the switch from infliximab i.v. to s.c. in patients with gastroenterological or rheumatological indication at month 12.Patients who are eligible but were switched before the inclusion in this study will also be enrolled, and the data already collected according to clinical practice and consistent with the study outcome measures will be used retrospectively. All patients will be followed up according to the standard of care of each participating center.The main questions it aims to answer are:To investigate the effectiveness at month 2, 6 and 12 after switching to infliximab s.c.To investigate the safety profile at month 2, 6 and 12 after switching to infliximab s.c.To investigate the difference between patients with rheumatological diseases and patients with IBD in terms of quality of life and work, effectiveness and safety at month 2, 6 and 12 after switching.To investigate the presence of baseline predictors for drug persistence at month 12 (sex, age, disease type, disease severity, body mass index, concomitant medications, smoking habit, presence of comorbidities).To investigate whether there is any change between baseline and week 52 in the following aspects:Job type and need for any authorization to go to the hospital to receive the study drugDistance and duration of the travel home-hospitalMode of travel home-hospitalNeed for a caregiver to be presentTime spent at hospitalPatient's preference for the way of study drug administration expressed on a 10-grades VAS scale.The study period for observation will be 12 months from the date of switch. At week 0, month 2, 6 and 12 from the date of the switch, clinical activity, safety data and biomarker levels will be collected.For those patients who have had an endoscopic evaluation of the disease within 2 months of inclusion and repeat the endoscopic evaluation at 12 months ± 8 weeks, endoscopic data will also be collected (valid only in the presence of IBD).In those centers where a blood sample to analyze the minimum levels and anti-drug antibodies of infliximab has been collected and/or stored within 2 months prior to the date of transition, the patient will be asked to give informed consent to the use of this sample and to provide a blood sample for the same analysis at week 0, month 2 and 12. These samples will be analyzed and compared to evaluate the immunogenicity of the drug. These analyzes will be centralized in one lab.

Inclusion Criteria:Male or female patient of ≥18 years age and no upper age limitPatients with confirmed diagnosis of at least one of the following conditions: Crohn's disease; ulcerative colitis; rheumatoid arthritis4 (2010 ACR/EULAR criteria); ankylosing spondylitis (according to the ASAS modification of the Berlin algorithm for diagnosing ankylosing spondylitis)5; psoriatic arthritis (CASPAR criteria)6.Exposed to i.v. infliximab for at least the minimum time required by the current SmPC, and switched to infliximab s.c. 120 mg q2w prior or at the time of to the inclusion in this study.Treatment with infliximab is according to local approved labelFull ability to understand the study procedures and to sign an informed consent formExclusion Criteria:a. Known intolerance/allergy/reaction to infliximab or any excipient included in the s.c. infliximab formulationNon confirmed diagnosis of IBD (unclassified IBD) or not classifiable as having RA or AxSpA or PsA according to the respective criteriaCardiac insufficiency grade IV according to the NYHA scaleActive infection at the time of inclusionPregnancy or lactation at the time of inclusionActive malignancy at the time of inclusion